Wegovy journey updates: what the real data says about GLP-1 results

What did @coach.mckissic actually say?

After seven months on Wegovy, starting between 295-298 pounds, he's down to roughly 254, a loss of over 40 pounds. He says his weight "didn't start coming off" until months five or six, which left him feeling like he'd been scammed. He also mentions losing interest in hobbies he used to love, like video games, and connects the weight loss journey directly to depression and self-image.

He's targeting a goal weight of 200-215 pounds and describes breaking into the 250s as an emotional milestone, one he hadn't hit in over a decade. He also frames obesity as a gateway to diabetes, high blood pressure, and shortened life, and says he was mentally prepared to accept those outcomes if this didn't work.

Does the science back this up?

The delayed response narrative is real and well-documented. Semaglutide's weight loss effect isn't linear, and early plateaus are common. The STEP 1 trial (Wilding et al., 2021, NEJM) showed the most significant weight reduction occurring between weeks 16 and 68, with early weeks often showing modest changes while the body adjusts to appetite suppression and dose escalation.

The anhedonia he describes, losing interest in video games and work, is more complicated. GLP-1 receptor agonists do act on reward pathways in the brain. Blum et al. (2022, Nutrients) and preclinical data suggest semaglutide reduces dopamine-driven reward signaling, which can dull cravings but may also blunt pleasure more broadly. This is not a widely publicized side effect, but it's not fabricated either. The FDA label for semaglutide does not list anhedonia explicitly, though mood changes are listed as potential adverse events. He's describing something real that medicine hasn't fully resolved yet.

What did they get wrong (or right)?

He got the delayed onset experience right. Many patients, especially those on dose titration schedules, don't see dramatic scale movement in the first few months. That's not a scam, that's pharmacology. Credit where it's due.

Where things get fuzzy is the framing around the anhedonia-like symptoms. He says, "I haven't really had the desire to do things I used to want to do," and attributes this implicitly to the medication. That may be accurate, but depression itself, which he also describes experiencing, is a major cause of anhedonia. Untangling whether the medication, the psychological journey of weight loss, or pre-existing depression is driving that symptom is something he can't do on TikTok, and neither can we. He should be talking to his prescriber about this specifically.

His equation of obesity with diabetes, hypertension, and shortened life is broadly supported by epidemiological data (GBD 2015 Obesity Collaborators, 2017, Lancet), though the relationship is probabilistic, not guaranteed.

What should you actually know?

A few things matter here for anyone watching this and considering or currently on a GLP-1 medication.

• Delayed weight loss in the first few months of semaglutide is normal. The STEP trials used a 16-week dose escalation, and significant fat loss often accelerates after reaching the maintenance dose of 2.4mg weekly.
• If you're experiencing loss of interest in activities you used to enjoy while on a GLP-1, tell your doctor. This could be medication-related reward pathway changes, depression, or both. It warrants a real clinical conversation, not a TikTok comment.
• Forty-plus pounds in seven months on semaglutide is within the range of what trials show, though results vary significantly by adherence, diet, activity, and individual metabolic response.
• His goal weight of 200-215 pounds at 6'4" puts him at a BMI of roughly 24-26, which falls within or just above the normal range. That's a clinically reasonable target, not an extreme one.

The emotional component he describes, depression tied to body image, the psychological weight of not looking how you used to, is under-discussed in GLP-1 conversations that tend to focus on pounds lost and A1c numbers. That part of his story deserves attention, not dismissal.